title: Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.
abstract: Colorectal cancer (CRC) is one of the most common human malignant diseases and the second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC has improved significantly in recent years. With the emergence of two targeted antibodies, cetuximab (Erbitux), an anti-epidermal growth factor receptor monoclonal antibody and bevacizumab (Avastin), a vascular endothelial growth factor monoclonal antibody, the treatment of metastatic CRC has entered the era of personalized therapy. Predictive and prognostic biomarkers have, and will continue to, facilitate the selection of suitable patients and the personalization of treatment for metastatic CRC (mCRC). In this review, we will focus primarily on the important progresses made in the personalized treatment of mCRC and discuss the potentially novel predictive and prognostic biomarkers for improved selection of patients for anti-cancer treatment in the future.
authors.affiliation: Hui-Yan Luo, Rui-Hua Xu, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Hui-Yan
authors.initials: HY
authors.lastname: Luo
authors.affiliation: Hui-Yan Luo, Rui-Hua Xu, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Rui-Hua
authors.initials: RH
authors.lastname: Xu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000068818:Cetuximab; D058534:Class I Phosphatidylinositol 3-Kinases; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D044127:Epigenesis, Genetic; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D009154:Mutation; D009389:Neovascularization, Pathologic; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011237:Predictive Value of Tests; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D018631:ras Proteins / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000068258:Bevacizumab; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human; D066246:ErbB Receptors; D019859:Proto-Oncogene Proteins c-met; D017526:Receptor, IGF Type 1; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D018631:ras Proteins; D000068818:Cetuximab
keywords: Advanced colorectal cancer; Biomarker; Predictive; Prognostic; Target therapy
references.citation: PLoS One. 2009 Oct 02;4(10):e7287
references.pmid: 19806185
references.citation: Mol Pathol. 2003 Jun;56(3):137-40
references.pmid: 12782759
references.citation: Oncol Rep. 2009 Jan;21(1):211-6
references.pmid: 19082464
references.citation: Ann Oncol. 2005 Nov;16(11):1848-9
references.pmid: 16012179
references.citation: Curr Cancer Drug Targets. 2010 Feb;10(1):80-95
references.pmid: 20088790
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2675-82
references.pmid: 21646616
references.citation: Br J Cancer. 2009 Aug 4;101(3):465-72
references.pmid: 19603024
references.citation: Br J Cancer. 2008 Jul 8;99(1):83-9
references.pmid: 18577988
references.citation: Ann N Y Acad Sci. 2004 Dec;1030:377-83
references.pmid: 15659820
references.citation: Mol Cancer Ther. 2012 Sep;11(9):2010-20
references.pmid: 22778155
references.citation: Cancer. 2001 Sep 1;92(5):1331-46
references.pmid: 11571750
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4217-9
references.pmid: 18757341
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4706-13
references.pmid: 20921462
references.citation: J Clin Oncol. 2008 Dec 10;26(35):5705-12
references.pmid: 19001320
references.citation: Int J Colorectal Dis. 2010 Feb;25(2):181-6
references.pmid: 19936766
references.citation: Nature. 1987 May 28-Jun 3;327(6120):293-7
references.pmid: 3587348
references.citation: Clin Colorectal Cancer. 2011 Dec;10(4):325-32
references.pmid: 21729677
references.citation: Ann Oncol. 2008 Apr;19(4):717-23
references.pmid: 17974556
references.citation: Cancer Res. 2002 Jan 1;62(1):200-7
references.pmid: 11782378
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1254-61
references.pmid: 20100961
references.citation: Surg Oncol. 2003 Nov;12(3):173-86
references.pmid: 12957621
references.citation: Br J Cancer. 2011 Mar 1;104(5):856-62
references.pmid: 21285991
references.citation: Lancet Oncol. 2010 Aug;11(8):753-62
references.pmid: 20619739
references.citation: N Engl J Med. 2008 Oct 23;359(17):1757-65
references.pmid: 18946061
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1
references.pmid: 18445856
references.citation: J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24
references.pmid: 19738166
references.citation: Clin Cancer Res. 2009 May 1;15(9):3184-8
references.pmid: 19366826
references.citation: J Clin Oncol. 2001 Jan 15;19(2):299-304
references.pmid: 11208819
references.citation: Cancer Res. 2009 Mar 1;69(5):1851-7
references.pmid: 19223544
references.citation: Gut. 2009 Jan;58(1):90-6
references.pmid: 18832519
references.citation: Cancer Cell. 2007 Jan;11(1):53-67
references.pmid: 17222790
references.citation: BioDrugs. 2011 Jun 1;25(3):159-69
references.pmid: 21627340
references.citation: Clin Exp Metastasis. 2008;25(8):843-54
references.pmid: 18696232
references.citation: Pharmacogenomics J. 2012 Dec;12(6):468-75
references.pmid: 21844885
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: Br J Cancer. 2009 Apr 7;100(7):1087-94
references.pmid: 19293803
references.citation: Br J Cancer. 2013 Feb 19;108(3):668-75
references.pmid: 23348520
references.citation: Clin Cancer Res. 2012 Apr 15;18(8):2257-68
references.pmid: 22357840
references.citation: Lancet. 2013 Jan 26;381(9863):303-12
references.pmid: 23177514
references.citation: Drugs Today (Barc). 2005 Feb;41(2):107-27
references.pmid: 15821783
references.citation: Ann Oncol. 2011 Jul;22(7):1535-1546
references.pmid: 21228335
references.citation: J Hematol Oncol. 2012 Aug 16;5:52
references.pmid: 22897982
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3930-5
references.pmid: 17761976
references.citation: J Clin Oncol. 2009 Dec 10;27(35):5924-30
references.pmid: 19884556
references.citation: Cancer Res. 2000 Dec 1;60(23):6750-6
references.pmid: 11118062
references.citation: Cancer Res. 2006 Apr 15;66(8):3992-5
references.pmid: 16618717
references.citation: J Clin Oncol. 2012 May 20;30(15):1755-62
references.pmid: 22473155
references.citation: Int J Cancer. 1994 Dec 15;59(6):747-51
references.pmid: 7989112
references.citation: Neoplasia. 2008 Jun;10(6):534-41
references.pmid: 18516290
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2622-9
references.pmid: 19398573
references.citation: N Engl J Med. 2004 Dec 30;351(27):2883
references.pmid: 15625347
references.citation: Eur J Cancer. 2010 Jul;46(11):1997-2009
references.pmid: 20413299
references.citation: Virchows Arch. 2007 May;450(5):529-37
references.pmid: 17372756
references.citation: J Clin Oncol. 2009 Feb 10;27(5):672-80
references.pmid: 19114685
references.citation: Int J Cancer. 2008 May 15;122(10):2255-9
references.pmid: 18224685
references.citation: Expert Opin Biol Ther. 2013 Feb;13(2):241-55
references.pmid: 23281932
references.citation: Cancer Lett. 2011 Oct 28;309(2):209-19
references.pmid: 21745712
references.citation: BMC Cancer. 2008 Aug 13;8:234
references.pmid: 18700047
references.citation: Lancet. 2011 Jun 18;377(9783):2103-14
references.pmid: 21641636
references.citation: Cell. 1990 Jun 1;61(5):759-67
references.pmid: 2188735
references.citation: Crit Rev Oncol Hematol. 2010 Jun;74(3):193-202
references.pmid: 19700342
references.citation: Cancer. 2009 Feb 15;115(4):760-9
references.pmid: 19127559
references.citation: Ann Oncol. 2010 Dec;21(12):2396-2402
references.pmid: 20501503
references.citation: Int J Cancer. 2007 Oct 15;121(8):1771-8
references.pmid: 17590872
references.citation: Br J Cancer. 2001 Sep 1;85(5):692-6
references.pmid: 11531254
references.citation: Clin Cancer Res. 2009 Nov 15;15(22):6956-62
references.pmid: 19903786
references.citation: Clin Cancer Res. 2008 Sep 15;14(18):5869-76
references.pmid: 18794099
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4914-21
references.pmid: 17050875
references.citation: J Clin Oncol. 2009 Oct 20;27(30):5068-74
references.pmid: 19738126
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: J Cancer Res Clin Oncol. 2013 May;139(5):891-900
references.pmid: 23435830
references.citation: J Clin Oncol. 2011 Apr 1;29(10):1382-91
references.pmid: 21220596
references.citation: Cancer Res. 2007 Mar 15;67(6):2643-8
references.pmid: 17363584
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3230-7
references.pmid: 17664471
references.citation: Oncol Rep. 2005 Feb;13(2):247-52
references.pmid: 15643506
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1850-8
references.pmid: 16551870
references.citation: J Clin Oncol. 2011 May 20;29(15):2011-9
references.pmid: 21502544
references.citation: J Natl Cancer Inst. 1998 May 6;90(9):675-84
references.pmid: 9586664
references.citation: J Clin Oncol. 2010 Mar 1;28(7):e111-2
references.pmid: 20008635
references.citation: N Engl J Med. 2005 Jul 14;353(2):208-9
references.pmid: 16014894
references.citation: Lancet Oncol. 2010 Dec;11(12):1172-83
references.pmid: 21126687
references.citation: N Engl J Med. 2009 Apr 2;360(14):1408-17
references.pmid: 19339720
references.citation: Cancer Cell. 2009 Jan 6;15(1):21-34
references.pmid: 19111878
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3499-506
references.pmid: 22949147
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61
references.pmid: 21129611
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5878-85
references.pmid: 16115929
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8822-7
references.pmid: 16723399
references.citation: Cancer Chemother Pharmacol. 2012 Jun;69(6):1647-55
references.pmid: 22610356
references.citation: J Clin Oncol. 2009 Feb 10;27(5):812-26
references.pmid: 19103723
references.citation: J Clin Oncol. 2010 Jan 20;28(3):466-74
references.pmid: 20008640
references.citation: Ann Surg Oncol. 2008 Aug;15(8):2129-36
references.pmid: 18478301
references.citation: Gastroenterology. 2008 May;134(5):1296-310
references.pmid: 18471507
references.citation: Ann Oncol. 2012 Jun;23(6):1518-25
references.pmid: 22039088
references.citation: JAMA. 2010 Oct 27;304(16):1812-20
references.pmid: 20978259
references.citation: Pharmacogenomics. 2008 Dec;9(12):1903-16
references.pmid: 19072647
references.citation: Crit Rev Oncol Hematol. 2008 Jan;65(1):8-20
references.pmid: 18006328
references.citation: Br J Cancer. 2009 Apr 21;100(8):1330-5
references.pmid: 19367287
references.citation: Ann Oncol. 2008 Mar;19(3):508-15
references.pmid: 17998284
references.citation: Eur J Cancer. 2012 Jul;48(10):1466-75
references.pmid: 22446022
references.citation: Clin Colorectal Cancer. 2011 Dec;10(4):279-89
references.pmid: 21729679
references.citation: Cancer Res. 2007 Dec 1;67(23):11244-53
references.pmid: 18056450
references.citation: Curr Cancer Drug Targets. 2010 Dec;10(8):824-33
references.pmid: 20718704
references.citation: PLoS One. 2011 Jan 20;6(1):e15980
references.pmid: 21283802
references.citation: Int J Clin Oncol. 2008 Dec;13(6):498-503
references.pmid: 19093176
references.citation: Semin Oncol. 2005 Feb;32(1):52-60
references.pmid: 15726506
references.citation: Lancet Oncol. 2005 May;6(5):279-86
references.pmid: 15863375
references.citation: Expert Rev Anticancer Ther. 2001 Aug;1(2):247-57
references.pmid: 12113030
references.citation: Crit Rev Oncol Hematol. 1999 Feb;29(3):209-48
references.pmid: 10226727
references.citation: Mod Pathol. 2004 Aug;17(8):895-904
references.pmid: 15143334
references.citation: Int J Oncol. 2006 Nov;29(5):1159-65
references.pmid: 17016647
references.citation: Ann Oncol. 2009 Jan;20(1):84-90
references.pmid: 18669866
references.citation: Oncologist. 2009 Mar;14(3):284-90
references.pmid: 19282350
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1803-10
references.pmid: 15677699
references.citation: PLoS One. 2013;8(2):e56205
references.pmid: 23441167
references.citation: J Clin Oncol. 2009 Feb 10;27(5):663-71
references.pmid: 19114683
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4697-705
references.pmid: 20921465
references.citation: Cancer Res. 1989 Sep 1;49(17):4682-9
references.pmid: 2547513
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1181-9
references.pmid: 20100964
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5268-72
references.pmid: 17000658
references.citation: Lancet Oncol. 2013 Jul;14(8):749-59
references.pmid: 23725851
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: J Clin Oncol. 2009 Dec 10;27(35):5931-7
references.pmid: 19884549
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7322-9
references.pmid: 19934290
references.citation: N Engl J Med. 2009 Feb 5;360(6):563-72
references.pmid: 19196673
references.citation: Cancer Biol Ther. 2006 Aug;5(8):928-32
references.pmid: 16969076
references.citation: Oncol Rep. 2008 Mar;19(3):697-704
references.pmid: 18288404
references.citation: Adv Clin Chem. 2010;51:71-119
references.pmid: 20857619
references.citation: Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9
references.pmid: 18003927
references.citation: Br J Cancer. 2009 Aug 18;101(4):715-21
references.pmid: 19603018
references.citation: J Clin Oncol. 2012 Oct 10;30(29):3570-7
references.pmid: 22734028
references.citation: N Engl J Med. 2013 Sep 12;369(11):1023-34
references.pmid: 24024839
references.citation: Br J Cancer. 2012 May 22;106(11):1718-21
references.pmid: 22531628